Associated Papers
Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer.
Yamazaki M et al.
Anticancer Research, 2023
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
Bruckmueller H et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
The influence of ABCG2 polymorphism on erlotinib efflux in the K562 cell line.
Svedberg A et al.
Pharmacology Research & Perspectives, 2020
Interindividual Regulation of the Breast Cancer Resistance Protein/ABCG2 Transporter in Term Human Placentas.
Bircsak KM et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2018
Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter.
Bircsak KM et al.
The Journal of Pharmacology and Experimental Therapeutics, 2016
Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.
Noguchi K et al.
Pharmacogenomics and Personalized Medicine, 2014
Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K et al.
Advanced Drug Delivery Reviews, 2009
Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.
Yanase K et al.
Cancer Letters, 2006
[Functional SNPs of the breast cancer resistance protein (ABCG2) gene altering the pharmacokinetics/pharmacodynamics of anticancer agents].
Sugimoto Y
Seikagaku. the Journal of Japanese Biochemical Society, 2005
Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.
Sugimoto Y et al.
Cancer Science, 2005
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Select a paper to view details